GSK international pharma chief leaves for Chiron

pharmafile | October 29, 2003 | News story | Sales and Marketing |  Chiron, David Stout, GSK, Howard Pien 

 

GlaxoSmithKline’s head of international pharmaceutical operations, Howard Pien, is to leave the company to become Chief Executive of Chiron.

Mr Pien’s departure for the Californian company represents the latest in a series of departures from the Anglo-American company’s top executives, and has forced another re-shuffle.

The departure last year of four senior R&D executives including the defection of James Palmer, Head of New Product Development, Research & Development, to rivals Bristol-Myers Squibb fuelled speculation that the mood in the company was not good, and that a post-merger re-organisation was not paying dividends.

Advertisement

But a marked upturn in new chemical entities coming through the pipeline has buoyed the company somewhat in the eyes of investors.

Mr Pien will be succeeded by Russell Grieg, currently Senior VP, Worldwide Business Development for R&D. Grieg will be based in London, and will report to David Stout, President, Pharmaceutical Operations.

Meanwhile, in Japan, Mark Dunoyer has been promoted to President of the company pharmaceutical operations.

Related Content

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

GSK’s Exdensur (depemokimab), a twice-yearly biological medicine, has received approval from the UK Medicines and …

Multiple myeloma treatment approved in Japan

GSK’s Blenrep (belantamab mafodotin) combinations have been approved by Japan’s Ministry of Health, Labour and …

The Gateway to Local Adoption Series

Latest content